Peptide-based medicines have established roles in diabetes, but the category includes products with different mechanisms and indications. Insulin and GLP-1-related medicines should not be treated as interchangeable simply because both involve peptides.

NIDDK explains that insulin and other medicines are selected according to diabetes type and individual needs. GLP-1 receptor agonists are among the treatments used to help manage blood glucose in type 2 diabetes. That role does not make them a universal replacement for insulin. NIDDK insulin medicines and other diabetes treatments

Match the medicine to the clinical question

An HbA1c change measures average glucose exposure over time. Weight, hypoglycemia, cardiovascular events and kidney outcomes are other questions. Evidence for one endpoint should not be assumed to answer all of them.

The actual product and indication matter as well. Tirzepatide is used in prescription products with defined labels. A label for one indication should be read as that product’s official information, not as a blanket set of instructions for every person with diabetes or every material carrying the ingredient name. Zepbound current prescription label

Trials do not erase individual risk

A participant’s background medicines, kidney function, medical history and treatment goals influence how trial findings apply. Some risks may depend on combinations with other glucose-lowering medicines. A clinician interprets these factors alongside the evidence rather than selecting treatment from a ranked list of peptide names.

A research review should also separate approved medicines from investigational candidates. A candidate that lowers glucose in a trial still needs product-specific evaluation and the relevant regulatory decisions before it can be described as an approved treatment.

AXON’s conclusion is that the strength of diabetes evidence comes from well-defined products, populations and outcomes. Research chemicals are not substitutes for prescribed medicines, and no treatment should be stopped or replaced on the basis of a general peptide article.